



2023 Impact Report





Thanks to You, We're Seeing Change

12 Years of Partnership with Northwestern Mutual

Improving the lives of children with cancer and their families through financial support, volunteerism and collaboration with partners to build stronger communities.

Receiving the Best Medicine

(Besides Laughter)

Six-year-old Arden is a giggle machine.

Ask her anything – her favorite color, her favorite thing about school, her favorite dance moves – the response is a giggle and a bright, beautiful smile that lights up her face.

And Arden has every reason to be giggly: she is celebrating three years of no evidence of disease after fighting childhood cancer.

It started with a stomach bug. At just 16 months old, Arden developed a series of low-grade fevers that had her daycare calling her parents continuously for two weeks. Arden's pediatrician took a second look and thought her spleen had enlarged. Arden was brought straight to the pediatric ER, where she had an ultrasound.

The images on the screen didn't look right. Arden's bloodwork came back abnormal. She was transported via ambulance to Children's Hospital of Philadelphia in the middle of the night, where she received an MRI. Arden had neuroblastoma.

The days that followed were a whirlwind of tests and treatment planning. While celebrating all the little miracles they could, Arden's family heard of a promising clinical trial led by ALSF-funded researcher Dr. Yael Mossé. Arden was a potential match, but needed more testing to determine if the trial was right for her. When testing revealed that Arden had high-risk neuroblastoma with the ALK mutation, she met the criteria to enroll in the trial. And it worked.

The treatment lasted more than three years, and as the final portion of her treatment, Arden completed taking a year of the trial drug, lorlatinib, in May 2023. In September that same year, Arden again celebrated having "No Evidence of Disease" thanks to this trial, and the research that led to it.

Someday, giggly Arden wants to spread her joy and help people, the way she was helped.

If it weren't for Alex, there wouldn't be any Ardens."

- Megan, Arden's mom







To our friends at Northwestern Mutual,

Your generous support means the world to kids fighting cancer, scientists finding cures, and us. So many promising research directions, treatments, support options for families, and more are possible today because you have been giving back every step of the way. We could never thank you enough for that.

From funding grants, to sponsoring special events, to balancing lemons on your heads and more, these steps have made a difference. We see how your creativity and dedication are changing the future for kids with cancer and want you to see it too. Thank you for all you do.



Gratefully,

Liz and Jay Scott

Alex's Parents & Co-Executive Directors
Alex's Lemonade Stand Foundation



About ALSF

Alex's Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of 4-year-old Alexandra "Alex" Scott, who was fighting cancer and wanted to raise money to find cures for all children with cancer. By the time Alex passed away at the age of 8, she had raised \$1 million. Since then, the Foundation bearing her name has evolved into a worldwide fundraising movement and the largest independent childhood cancer charity in the U.S. ALSF is a leader in funding pediatric cancer research projects across the globe and providing programs to families affected by childhood cancer.







12 Years of Partnership, 12 Years of Impact (Est. 2012)



\$32+ Million
Contributed By
Northwestern
Mutual Since 2012



\$3.5+ Million Contributed By Northwestern Mutual in 2023



Over 380 Research Grants Supported (16 Co-Funded Grants Awarded in 2023)



More Than 600,000 Research Hours Funded



12 Young
Investigators
Summits
Supported



Founding Partner of the Data Lab, Young Investigator Summit and Crazy 8 Initiative

Funding Areas Since 2012...



69 POST Grants

46 Young Investigator Grants

6 Crazy 8 Awards

11 Innovation Grants

12 Research Catalysts

3 Phase I/II Infrastructure Grants

6 Psychosocial Family Impact Grants

1 Reach Grant

1 'A' Award Grant

1 R Accelerated Grant

1 Bio-Therapeutics Impact Grant

2 Epidemiology Grants

213 Research Equipment Grants

13 Young Investigator Resource
Sharing Awards

21 Young Investigator Shark Tank Awards





Paving the Path to Discover More Cures

Your dedication to advancing childhood cancer research is making the future brighter for children with cancer and pediatric cancer researchers alike. In the last 12 years, Northwestern Mutual's support of research grants from early career scientists bringing new ideas to translating promising discoveries into clinical trials has made an amazing impact for families affected by childhood cancer.

Kids diagnosed today have more, safer treatment options available to them thanks to the research you've helped fund. Here's a snapshot of how you've supported researchers searching for breakthroughs.

Jessica Tsai, MD/PhD

2020 Young Investigator Grantee

When Dr. Jessica Tsai first received her Young Investigator Grant in 2020, she was working at the Dana-Farber Cancer Institute in Boston. The grant fueled her research on FOXR2, a mutated gene that is thought to drive the development of several human cancers. One is a largely incurable pediatric brain cancer called diffuse intrinsic pontine glioma (DIPG). The work centers around discovering how FOXR2 makes DIPGs grow and how to therapeutically target the gene to stop it from becoming DIPG. DIPG tumors mix with healthy tissue in the brain, making them inoperable, unstoppable, and deadly; only 10% of children live more than two years after diagnosis. Dr. Tsai recognizes the significant need to develop therapeutic strategies that improve the outcome and quality of life for children with DIPG. She is opening her own lab in Los Angeles to continue the important research the Young Investigator Grant helped her start.





Lia Gore, MD

2013 Infrastructure Grantee

In 2006, Dr. Lia Gore received one of our earliest grants to support the then-new Experimental Therapeutics Program at her hospital in Denver. The program sought to give children with little hope and even fewer childhood cancer treatment options access to cutting-edge treatments. A case file for a 3-year-old girl with relapsed cancer crossed Dr. Gore's desk. The girl had exhausted both standard and experimental treatments. Her family was desperate. Dr. Gore enrolled the girl in a Phase I study. Two weeks later, she was in complete remission. In 2013, Dr. Gore received an Infrastructure Grant co-funded by Northwestern Mutual. This allowed her to continue researching new treatments and providing access to more clinical trials for children in need of more options. Still a pediatric oncologist, Dr. Gore has shifted her focus to developing programs, mentoring other oncologists, and collaborating on large-scale initiatives in the childhood cancer space.



Elias Sayour, MD/PhD

2022 'R' Accelerated Grantee

Dr. Elias Sayour is a pediatric oncologist and Associate Professor of Neurosurgery and Pediatrics at the University of Florida Health. In 2022, Dr. Sayour received our 'R' Accelerated Award that was co-funded by Northwestern Mutual. This allowed him to further the development of a groundbreaking therapy that strengthens the immune response against glioblastoma, a cancer that only 5% of people can live more than five years with. The treatment involves taking part of someone's own tumor and putting it in a vaccine. Early results showed the immune system was successfully reprogrammed to attack the tumor, and they are now starting a clinical trial. Dr. Sayour hopes to study this breakthrough in a larger group of kids and adults in the near future.








Young Investigator Summit

In 2012, Northwestern Mutual approached us with the proposal for a unique symposium: one that would offer new research grantees the opportunity to meet other grantees, explore scientific collaboration, forge new relationships and interact with some of the leading researchers in the pediatric oncology field. The first Young Investigator Summit was held in October 2012 at Texas Children's Hospital in Houston, and has since been held in several cities across the country, including Milwaukee, Chicago, Los Angeles and Philadelphia. Hundreds of ALSF-funded scientists have been invited to share their findings and accelerate the search for pediatric cures. This fall, the Young Investigator Summit is celebrating its 12th year and will once again be held at Northwestern Mutual's Headquarters in Milwaukee, WI.



This annual summit is a success thanks to you, and a true testament to Northwestern Mutual's commitment to finding a cure for all childhood cancers.

This summit is bringing together so many young people, many of which will be your colleagues for the next 10, 20, 50 years maybe. So, this small scale format allows you to meet people, get to know them personally."

— 2018 Young Investigator Grantee, Nick van Gastel, PhD



POST grantee Reba Manicheril



POST grantee Nerea Goni



POST grantee
Paul Saah

Fueling Future Scientists

From the Very Start

Students interested in pediatric oncology research have the chance to experience the field firsthand as part of our Pediatric Oncology Student Training (POST) program. In partnership with Northwestern Mutual, the POST program was redesigned in 2021 to provide opportunities for underrepresented racial and ethnic groups to pursue paid internships in the scientific workforce. With nearly 75 POST grants co-funded by Northwestern Mutual over the years, your impact is giving budding researchers a chance to start paving their own path toward cures for more pediatric cancers.

After receiving a Wilms tumor diagnosis when she was 5 years old, **Reba Manicheril** knows the intricacies of survivorship firsthand. This year, she was awarded a POST grant to conduct research at Children's Hospital of Philadelphia in "Addressing Health Disparities in Childhood Cancer Survivorship Care" under the mentorship of Dr. Lisa Schwartz. To better understand disparities in survivorship care, healthcare utilization and health outcomes, their team is developing and testing intervention methods to re-engage survivors.

Nerea Goni received her POST award to study retinoblastoma – the most common pediatric eye cancer – under the guidance of Dr. Jesse Berry at Children's Hospital Los Angeles. At the age of 3, Nerea lost her left eye to this very cancer, but now, her research is trying to prevent other kids from experiencing the same things she did. Her project focuses on identifying effects of genomic changes in retinoblastoma using a liquid biopsy, with the end goal of improving the quality of a child's prognosis and treatment.

Paul Saah is using his POST grant to focus on the incidence and grades of adverse events during treatment for pediatric acute lymphoblastic leukemia at Emory University with the help of his mentor, Dr. Tamara Miller. In high school, Paul witnessed one of his soccer teammates struggle to return to the field because of the side effects from chemotherapy while fighting Hodgkin lymphoma. Now, Paul aims to improve understanding of the risks and management of toxicity during chemotherapy by utilizing data to describe the incidence and severity of such toxicities in kids with cancer.



Closing the Distance to **Cures**

Thanks to the yearly efforts made by Northwestern Mutual, families have access to potentially life-saving treatment for their child no matter where it is. When a devastating childhood cancer diagnosis is made and initial treatments aren't effective, the best option available to a child might be far from home. Northwestern Mutual has supported our Travel For Care program since its inception, which provides financial aid to these families so they can reach the therapies and clinical trials they need. It is there to help kids like Seth.

Seth is a resilient fighter. He is spunky and can be friends with anyone. He never misses a social event, even when battling cancer!

Before Seth's diagnosis, his parents noticed he had a rash that caused them concern. Not long after, doctors said Seth had acute lymphoblastic leukemia and he began treatment. This meant two CAR T-cell therapies, two bone marrow transplants, a clinical trial, four relapses and countless trips out-of-state.

When Seth had to leave his home in Kentucky for treatment, the Travel For Care program was there to relieve the family's financial burden. His main hospital was in Ohio, and he had to go to Philadelphia more than ten times. Because of your support for the Travel For Care program, Seth was able to access the treatment that brought him to remission.

Seth's family could not be prouder of how brave their little fighter is. Seth loves hosting his own lemonade stands so that programs like Travel For Care can keep helping other kids like him.


ALSF means that any family that is in need can receive support." — Michelle, Seth's mom



6 Don't give up, keep fighting."

 —Inspiring words from childhood cancer hero Seth





Thank You for Helping Our Heroes

Today, childhood cancer hero Marcel continues to be in remission thanks to the support his family received from the Travel For Care program.

Without that support, we would have to worry about how we would get to clinic visits and treatments... We had bigger things to worry about, like Marcel's reaction to chemo." — Ana, Marcel's mom

Thank you for being a Founding Partner of The Crazy 8 Initiative!



Above, teams funded through our Crazy 8 Grants traveled from all over the world to gather in Philadelphia in April 2024 to share progress on their projects, collaborate, and make valuable connections.



Updates from our Largest, Most Ambitious Childhood Cancer Research Grants

In 2020, we launched our largest, most ambitious grant category ever — the Crazy 8 Initiative. More than just a funding source, the Crazy 8 is our answer to how to cure the (so far) incurable childhood cancers. The Crazy 8 Initiative brings together multidisciplinary teams from all the around the world to study, collaborate, and ultimately make breakthroughs in the search for cures for the deadliest childhood cancers. They meet monthly over Zoom, travel to one another's labs, and also gather each year in Philadelphia to problem solve and share progress and technology.

Together, these scientists are making a difference, one incredible discovery at a time. As a Founding Partner of the Crazy 8 Initiative, Northwestern Mutual has sparked amazing advancements for these researchers to pursue cures for all kids with cancer.

Four years into their work, our six inaugural Crazy 8 teams have made landmark progress in their projects and they aren't stopping there.

Crazy 8 Initiative





Dr. Leonard Zon at the 2024 Crazy 8 Summit

- From his lab at St. Anna Children's Cancer Research Institute in Austria, **Heinrich Kovar, PhD,** is leading the Crazy 8 project studying Ewing sarcoma. His team has had exciting success using Zebrafish models to find the types of cells that are susceptible to becoming cancer. The team is working to establish an atlas that charts human cell development as it relates to bone sarcoma development, to help better understand when normal cells become sarcoma.
- The holy grail of cancer targets, MYCN, has long been considered undruggable and also an indicator of poor outcomes when it is found in neuroblastoma and medulloblastoma tumors. But, **Yael Mossé, MD,** from Children's Hospital of Philadelphia and her international team is working to change that. The team developed hybrid molecules that can specifically attach to MYCN and trick the cancer cells' own internal machinery to dissolve MYCN, which will lead to cancer cell death. Also exciting: Dr. Mossé and her team were recently awarded a \$25 million grant funded through Cancer Research UK, Institut National Du Cancer and KiKa (Children Cancer Free Foundation) through Cancer Grand Challenges, a UK-based initiative, to expand their research to other pediatric cancers.
- The team co-led by **Leonard Zon, MD, (Boston Children's Hospital) and Ross Levine, MD, (Memorial Sloan Kettering Cancer Center)** is using cellular barcoding to trace leukemia back to its roots to find the moment a normal blood cell turns into a cancerous blood cell and then develop targeted, less toxic therapies. The team has already made significant discoveries which have led to high-impact publications in *Cell* and *Nature*, further expanding the body of knowledge and continuing to push pediatric leukemia research forward. The team, which spans from Washington to Boston to Switzerland, has also developed and distributed a novel genetic model of leukemia that enables researchers to use barcoding in lab experiments efficiently and cost-effectively. The model has been distributed to more than 15 investigators and also deposited in the Jackson Labs repository, ensuring even more access to this breakthrough model.

As the project continues, they've turned their focus to recruiting kids with leukemia to the study, sequencing their cancer, and validating those results with lab models. The end goal isn't just a better understanding of leukemia origins, it's better treatments and cures. "The patients are the motivation. We need to do better," said Dr. Zon.





Dr. Yael Mossé in her lab

- Glue sounds like an unlikely tool for a pediatric oncology researcher. But for **Charles Mullighan, MBBS** (Hons), MSc, MD, from St. Jude Children's Research Hospital and his Crazy 8 project team, molecular glue offers the promise for effective treatments and cures for children with brain tumors and leukemia. Working together across expertise and disciplines, Dr. Mullighan's team has designed a collection of several thousands of molecular glues that have the potential to degrade cancer cells. Those glues were screened across a panel of leukemia and medulloblastoma cell lines, resulting in the identification of several potential glues that could stop tumors in experimental models.
- For kids with osteosarcoma, one of the most common types of bone cancer, treatments haven't changed much in decades. Treatments can be effective, but if the disease spreads, the chance of remission lessens significantly. Rani George, MD/PhD, from Dana-Farber Cancer Institute, leads the Crazy 8 team working to understand gene behavior in osteosarcoma to better understand the steps that happen to change osteosarcoma from a localized bone tumor to a deadly lung tumor. On her multi-disciplinary team is Ruben Dries, PhD, who is utilizing a technology called spatial biology to study the organization and structure of single cells of cancer to map out specific connections that lead to the spread of cancer to the lung.
- Alejandro Sweet-Cordero, MD, leads an international team that is also studying osteosarcoma, but with a different approach. Osteosarcoma is extremely heterogenous meaning that within a tumor no two cells are alike. This makes treatment difficult; because some cells may respond to therapy and others may not.

By using new technology developed by team member Dr. Ana Obenauf, the team will identify and isolate osteosarcoma cells with increased resistance to therapy or increased ability to form metastasis, enabling early intervention that will change the fight against osteosarcoma. His team includes researchers from four different institutions with specialties in molecular pathology and oncology.

dad. It's
heartbreaking
to know the
stories of kids
who have so
much potential,
but then
don't get the
opportunity."
— Dr. Ruben Dries

Crazy 8 Initiative

Thank you for being a Founding Partner of the Data Lab!

Empowering Pediatric Cancer Experts Poised for the Next Discovery to Help Kids

We started the Childhood Cancer Data Lab in 2017 to address the hurdles that slow down the pace of researchers in their search for new treatments to help kids with cancer. Massive amounts of data is publicly available, but collecting, sharing and utilizing it can be challenging. The Data Lab's goal is to put resources and knowledge in the hands of pediatric cancer experts to accelerate the pace of finding cures. **Northwestern Mutual is a Founding Partner of the Data Lab, and has made it possible for us to create unprecedented resources and train hundreds of researchers in this community so they can help more kids.**

Training Workshops

Our Data Lab holds training workshops that teach childhood cancer researchers how to better examine their data. These skills help them pursue projects with the highest potential to help kids fighting cancer. Past workshops have been hosted at Northwestern Mutual offices in Houston and Chicago!

Over the past year, the Data Lab has trained 90 researchers on topics including single-cell RNA-Sequencing and reproducible research practices. They also developed a new course requested by researchers from The Center for Data-Driven Discovery in Biomedicine at Children's Hospital of Philadelphia. It covered working collaboratively on analytical code and project management. The content was based on the Data Lab's expertise in setting up data-intensive research for success and tailored to meet the specific needs of the training group. It will be repurposed for broader audiences in the future.

Single-cell Pediatric Cancer Atlas (ScPCA)

The ScPCA Portal is a growing database of uniformly processed single-cell data from pediatric cancer tumors and model systems. Currently, it contains data from 518 samples representing 50 pediatric cancer types. As of April 2024, the ScPCA manuscript is available on *bioRxiv*, a widely used preprint server.

Initially, all data on the Portal were generated from projects funded by ALSF. To expand the ScPCA in a cost-effective way, the Data Lab has made it possible for other researchers to share their existing single-cell data on the Portal. In 2023, they launched a call for submissions from the pediatric cancer research community and have since added two community-contributed datasets. Eligible contributors received small one-time grants to be used for childhood cancer research.







Data Lab training workshop

Open Single-cell Pediatric Cancer Atlas (OpenScPCA)

Our Data Lab knows from training hundreds of researchers in analysis that making data available is not enough to change the future for children with cancer. Over 300 users have downloaded datasets from the ScPCA Portal, but they must be able to use this information to answer their scientific questions. In 2024, the Data Lab launched OpenScPCA, a collaborative project to analyze and improve the utility of the ScPCA data. It uses an open contribution model designed to allow experts worldwide to contribute and rapidly share results in real-time.

OpenScPCA is built on the success of previous Data Lab endeavors. They have already completed a project with a similar model called the Open Pediatric Brain Tumor Atlas. Over 60 collaborators from across the world openly analyzed and improved the data from 1,000 pediatric brain tumors. This work was published in *Cell Genomics* in 2023.

Through ScPCA, the Data Lab has learned that small grants effectively incentivize researchers interested in sharing. To motivate OpenScPCA collaborators and help sustain their engagement, they will implement a system of grants for completing analyses. Collaborators will develop transferable skills and learn to use powerful tooling for reproducible research and software development.

The Data Lab successfully obtained a grant from Amazon Web Services to set up infrastructure to give collaborators access to high-performance computing. Recently, the Data Lab used training material they previously developed in another workshop designed to onboard potential OpenScPCA contributors, another key step in the Data Lab's goal of helping researchers accelerate their path to new discoveries.

refine.bio

refine.bio makes vast amounts of data immediately usable and openly available to researchers everywhere. Over 8,000 datasets have been processed for download, saving countless hours of researcher time that can be spent on helping discover new treatment opportunities for kids fighting cancer. The tutorial website, refine.bio examples, shortens the learning curve for users less familiar with the analyses on the site. Over 26,000 visitors accessed the examples in 2023.



Epidemiology Grant

\$200,000 over two years

These grants are designed to support the research of investigators who have a specific focus on the epidemiology, early detection, or the prevention of childhood cancer.

Determining Social Risk Factors for Poor Outcomes in Pediatric Cancer Using Children's Oncology Group Registries

Anne Kirchhoff, Ph.D./MPH University of Utah 2019 Grant

Equipment Grants

Amount and timing may vary

Closed grants specific to Northwestern Mutual, Equipment Grants are given to pediatric cancer researchers by local NM offices.

Automatic Cell Counter from Northwestern Mutual's King of Prussia Office

Yael Mosse, M.D. The Children's Hospital of Philadelphia 2017 Grant

Centrifuge For Onsite DNA Sample Processing in Kenya—from Northwestern Mutual's Indianapolis Office

Terry Vik, M.D. Indiana University 2017 Grant

Compassion Fund—from Northwestern Mutual's Des Moines Office

Brenna Finnerty UnityPoint Health Foundation 2017 Grant

Computer for lab and gift cards for patient families in need—from Northwestern Mutual's St. Louis Office

Jeffrey Magee, M.D./Ph.D. Washington University 2017 Grant

Digital Mouse Stereotaxic Instruments from Northwestern Mutual's New York Office

David Lyden, M.D./Ph.D.
Weill Medical College of Cornell University
2017 Grant

Flow Hood—from Northwestern Mutual's Middleton Office

Paul Sondel, M.D./Ph.D. University of Wisconsin - Madison 2017 Grant

Four Infusion Chairs and a Mobile Phlebotomy Cart for New Clinic—from Northwestern Mutual's St. Louis Office

Todd Druley, M.D./Ph.D. Washington University School of Medicine 2017 Grant

High-Powered Lens for Fluorescent Microscope—from Northwestern Mutual's Gainesville Office

Catherine Flores, Ph.D. University of Florida 2017 Grant

New computer for lab and gas cards for families in need—from Northwestern Mutual's Chicago Office

Susan Cohn, M.D. University of Chicago 2017 Grant

Parking Vouchers for Patient Families from Northwestern Mutual's Albany Office

Angie Silipigno, Certified Child Life Specialist, Albany Medical Center 2017 Grant

Patient Emergency Fund for Emergency Expenses—from Northwestern Mutual's Fort Lauderdale Office

Nancy Vidaurre, Joe DiMaggio Children's Hospital Foundation 2017 Grant

Patient Emergency Fund for Emergency Expenses—from Northwestern Mutual's Manchester Office

Sharon Brown, Children's Hospital at Dartmouth Hitchcock- DH Health 2017 Grant

PCR Machine and Multi-Channel Pipette from Northwestern Mutual's Columbus Office

Kathleen Pishas, Ph.D. Research Institute at Nationwide Children's Hospital 2017 Grant

Refrigerated Microcentrifuge and GoBlot Western Blot Processor—from Northwestern Mutual's Milwaukee and Appleton Offices

Nathan Schloemer, M.D. Children's Hospital of Wisconsin 2017 Grant

Start-up funds for Pediatric Oncology support groups - from Northwestern Mutual's Orlando Office

Emily Owens Pickle, CCRP Arnold Palmer Children's Hospital 2017 Grant

Thermomixer for Lab—from Northwestern Mutual's Wellesley Office

David Debruyne, Ph.D.
Dana-Farber Cancer Institute
2017 Grant

Two Laptops and Patient Garden Shade from Northwestern Mutual's San Diego Office

Paula M. Aristizabal, M.D. Rady Children's Hospital 2017 Grant

Webinar equipment to connect various locations and gas cards for patient families—from Northwestern Mutual's Leawood Office

Tom Curran, Ph.D. Children's Mercy Hospital 2017 Grant

Innovation Grants

\$250,000 over two years

Innovation Grants are designed to provide critical and significant seed funding for experienced investigators with a novel and promising approach to finding causes and cures for childhood cancers.

Ectopic Neuroligin Signaling in Pediatric Glioblastoma

Alex Shcheglovitov, Ph.D. University of Utah 2023 Grant

Blocking the Evil Messenger in MYCNdriven High-risk Neuroblastoma

Hui Feng, M.D./Ph.D. Boston University 2022 Grant

Epigenetic Enhancement of MHCI to Augment Neuroblastoma Immunotherapy

Paul M. Sondel, M.D./Ph.D. University of Wisconsin - Madison 2022 Grant

Pediatric Osteosarcoma: Identifying the Elusive Molecular Signature and its Relationship to this Disease

Linda Hendershot, Ph.D. St. Jude Children's Research Hospital 2019 Grant

Nuclear Receptor Tyrosine Kinases Mediating Chromatin Remodeling & Checkpoint Adaptation

Charles Keller, M.D. Children's Cancer Therapy Development Institute 2018 Grant

RNA-ECS to quantify rare clonal RNA species at diagnosis, remission and relapse from the COG AAML1031 study

Todd Druley, M.D./Ph.D. Washington University 2018 Grant

RNA methylation in metabolically disrupted pediatric cancers

Patricia Dahia, M.D./Ph.D. University of Texas Health Science Center at San Antonio 2018 Grant

Targeting KDM6B in Pediatric Leukemia

Grant Challen, Ph.D. Washington University 2018 Grant

Development of Mithramycin Analogs for Ewing Sarcoma

Patrick Grohar, M.D./Ph.D. Van Andel Research University 2017 Grant

R Accelerated

\$800,000 over four years

R Accelerated Grants provide funding for an original project focused on accelerating the discovery of a more effective therapy. Recipients must have previously received a pediatric cancer-focused R01 grant from the National Institutes of Health.

Phase I Trial of Multilamellar mRNA Lipid Particles for Recurrent Pediatric High-Grade Glioma

Elias Sayour, M.D./Ph.D. University of Florida 2022 Grant

Pediatric Oncology Student Training (POST) Grants

\$5,000 over a three-month period

The Pediatric Oncology Student
Training (POST) Program is designed for
undergraduate, graduate and medical
students who have an interest in pediatric
oncology research and would like to
experience the field first hand. Students train
with a pediatric oncology research mentor.

Effects of standardized, prospective Epstein-Barr virus (EBV)

Maanasi Gothoskar, Children's Hospital of Philadelphia 2024 Grant

Epigenetic Control of Cell State in Retinoid Resistant Neuroblastoma

Sadhvi Sreeram, Dana-Farber Cancer Institute 2024 Grant

Identification of Phenotypic Effects of Genomic Changes in Retinoblastoma Tumors Using an Aqueous Humor Liquid Biopsy

Nerea Goni, Children's Hospital Los Angeles 2024 Grant

IL7 Signaling Enhanced CAR T Cells to Treat Pediatric Solid Tumors

Haydee Rochits Cueto, Baylor College of Medicine 2024 Grant

Incidence and Grades of Adverse Events During Treatment for Pediatric Acute Lymphoblastic Leukemia

Paul Saah, Emory University 2024 Grant

Exploring the role of TP53 mutations in the radioresistance of Diffuse Intrinsic Pontine Glioma (DIPG)

Angelica Rivera-Martinez, University of Kentucky 2023 Grant

FGFR1 Alterations in Pediatric Gliomas

Angela Deleon, Dana-Farber Cancer Institute 2023 Grant

Identification and Characterization of non-P53 Stress Pathways in Shwachman-Diamond Syndrome

Amelie Cotta, The Cleveland Clinic 2023 Grant

Investigating the Role of the MYCN Oncogene in Regulating Chemokine Expression in Neuroblastoma

Mykaela Salvacion, Children's Hospital of Philadelphia 2023 Grant

Maternal Comorbid Conditions and the Risk of Pediatric Cancer

Tobiloba Adanma Adenekan, University of North Texas 2023 Grant

Neuronal Regulation of Pediatric Brain Tumor Growth

Lara Isabel Marco Y Marquez, Washington University School of Medicine 2023 Grant

Structural Rearrangement Signatures as Novel Biomarkers for Homologous Recombination Deficiency in Cancer

Ahado Ali, Dana-Farber Cancer Institute 2023 Grant

Synthetic Gene Expression Regulatory Switch Engineered CAR T Cells for Children with Cancer

Yaery Jazmin Salvador Lopez, Baylor College of Medicine 2023 Grant

Understanding the Association Between Genetic Polymorphisms and Adverse Events During Therapy for Acute Lymphoblastic Leukemia

Jazmin Huerta, Emory University 2023 Grant

Using Rapid Protein Degradation to Determine the Effect of RUNX1 Loss-offunction on DNA Damage Accumulation and Repair

Jackriel Pina Morales, Einstein Medicine 2023 Grant

Characterizing Therapeutic Vulnerabilities in Mismatch Repair Deficient Pediatric High-grade Gliomas

Kitty-Anne Dubuisson, Dana-Farber Cancer Institute 2022 Grant

Defining Genetic Drivers Mutations, Clinic Characteristics & Outcomes in Children & Young Adults with Histiocytoses

Christan Dillard-Ilboudo, Baylor College of Medicine 2022 Grant

Exploring the Immune Effects of Photodynamic Therapy Treatment on Diffuse Midline Glioma Progression

Gabrielle Price, Icahn School of Medicine at Mount Sinai 2022 Grant

Families of Children with Advanced Cancer: The Impact of Social Determinants of Health

Myanah Keys, Research Institute at Nationwide Children's Hospital 2022 Grant



Financial Toxicity at End-of-Life and Beyond

Ariel Alexander, University of Alabama at Birmingham 2022 Grant

IL15/TGF-beta Trap Fusokine for Treatment of Pediatric Sarcomas

Brittany Russell, University of Wisconsin 2022 Grant

Patterns of Ewing Sarcoma Metastases in a Zebrafish Human Xenograft Model

Jennifer Stiene, The Cleveland Clinic 2022 Grant

The Interplay Between DNA Damage and Histone Mutations in Pediatric Gliomas

Annarah Charles, Dana-Farber Cancer Institute 2022 Grant

Understanding Disparities in Pediatric Solid Tumor Oncology Trial Enrollment

Oludamilola T. Taiwo, Emory University 2022 Grant

Wilms Tumor Risk and Management in WAGR Syndrome

India Cannon, Children's Hospital of Philadelphia 2022 Grant

A Multi-omics Approach to Defining the Differential Impact of IL-15 Versus IL-21 on Mature NK Cells

Evelyn Navarro, Research Institute at Nationwide Children's Hospital 2021 Grant

Deep Phenotyping of Early Cardiotoxicity in Pediatric AML

Andrew Siaw-Asamoah, University of Pennsylvania 2021 Grant

Defining Features of Relapse Predictive Cells in ALL

Dorra Jedhoui, Stanford University 2021 Grant

Disparities in Relapsed Pediatric AML Therapy

Beinaka Tomlinson, Children's Hospital of Philadelphia 2021 Grant

Dissecting and Targeting Apoptotic Resistance in Pediatric Leukemia

Alexander Gousie, Dana-Farber Cancer Institute 2021 Grant

Effects of Center-level Resources on Septic Shock and Mortality Incidence in Children with Acute Leukemia

Modesty Obasohan, Children's Hospital of Philadelphia 2021 Grant

Elucidating HMGA1 Pathways to Target in Therapy for Refractory MLL-rearranged Pediatric Leukemia

Fidelia Asomani, The Johns Hopkins University School of Medicine 2021 Grant

Impact of Pediatric Germline Testing in a Pediatric Cancer Predisposition

Cristle Ike, Children's Hospital of Philadelphia 2021 Grant

Isogenic Models of Pediatric AML for Interrogating Different Ras Pathway Mutations

Marcos Armendáriz, University of California San Francisco 2021 Grant

Laboratory Correlates of CAR T-Cell Reinfusion

Kirubel Alemu Gebre, Children's Hospital of Philadelphia 2021 Grant

Ototoxicity and Language Development in Pediatric Germ Cell Tumor Survivors

Pablo Monterroso, University of Minnesota 2021 Grant

Targeting ALK Fusions in Monosomy 7 AML

Makia Krysten Manselle, Fred Hutchinson Cancer Research Center 2021 Grant

Be a Dog's Best Friend, Help a Child

Ashish Vaswani, Children's Cancer Therapy Development Institute 2018 Grant

Characterizing PPM1D mutations as oncogenic drivers of Diffuse Intrinsic Pontine Glioma

Spandana Jarmale Dana-Farber Cancer Institute 2018 Grant

Identifying drivers of Ewing Sarcoma using engineered iPSC of European and African ancestry

Kai Vorhies, University of Minnesota 2018 Grant

Investigating the interplay between nucleophosmin and caspase-2 in determining chemosensitivity in childhood AML

Kenneth McSherry, Baylor College of Medicine 2018 Grant

PDL-1 Expression on Tumor Cells Mediates C8 Cytotoxic T cell (CTL) Resistance

Taylor Pearl, The Research Institute at Nationwide Children's Hospital 2018 Grant

Phenotype of tumor-associated antigen-presenting cells after blocking indoleamine 2-3-dioxygenase

Rachel Vaizer, Augusta University 2018 Grant

Quantitative Evaluation of CAR-T Cell Inhibition Mediated by PD1

Kevin Huang, University of Michigan 2018 Grant

Targeted Inhibition of CREB for the Treatment of Pediatric Acute Myeloid Leukemia

Yvonne Lee, Stanford University 2018 Grant

Targeting SHP2 in Receptor Tyrosine Kinase-driven neuroblastomas

Sabina London, The Children's Hospital of Philadelphia 2018 Grant

The Role of Neuropeptide Y and its Y5 Receptor in Dissemination of Refractory Neuroblastoma

Lindsay Anne Caprio, Georgetown University 2018 Grant

A Characterization of TP53 Mutations among Pediatric Osteosarcoma Cases

Brandon Diessner, University of Minnesota 2017 Grant



ABVD without Radiation for Newly Diagnosed Pediatric Patients with Hodgkin lymphoma: A Single Center Retrospective Analysis of 22 Consecutive Patients

Tu Dinh, University of California San Francisco 2017 Grant

Adoptive Cell Therapy against Brain Stem Gliomas

Brandon Wummer, University of Florida 2017 Grant

Characterizing Novel Rearrangements in Diffuse Intrinsic Pontine Glioma

Yohanna Georgis, Dana-Farber Cancer Institute 2017 Grant

Cutting off the Oncogenic Signals that Cofactors Send to Notch in T-ALL

Paula Jeon, University of Michigan 2017 Grant

Identifying Novel Epigenetic Dependencies in Pre-leukemic Hematopoietic Stem Cells

Emily Haussler, Washington University School of Medicine 2017 Grant

Investigating the Effects of Indoleamine 2-3-Dioxygenase Pathway Blockers in Combination with Chemotherapy and Radiation

Yannan (Jennifer) Wang, M.D. Augusta University Research Institute 2017 Grant

A Novel Separase Inhibitor, Sepin-1 for Neuroblastoma Treatment

Siddharth Gorantla, Baylor College of Medicine 2017 Grant

Parental Report of Sleep Hygiene and Sleep Quality in Children with Cancer: Implications for the Development of a Family

Hyun (Monica) Kim, Boston University 2017 Grant

Racial Disparities in Pediatric Acute Leukemia

Tyler Galvelis, The Children's Hospital of Philadelphia 2017 Grant

Reactivation of p53-Mediated Apoptosis in Neuroblastoma

Emily Crawford, Dana-Farber Cancer Institute 2017 Grant

Role of Health Literacy on Psychological Distress in Parents of Newly Diagnosed Pediatric Cancer Patients at Rady Children's Hospital San Diego

Shilpa Nataraj, University of California, San Diego 2017 Grant

Psychosocial Family Impact Grants

\$300,000 over three years

Psychosocial Grants fill a direct need for research funding by supporting studies that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer. These grants are designed to fund established researchers who have novel approaches to understanding the psychosocial aspects of pediatric cancer whose proposals will have a clinically significant impact.

Impact of Pediatric Germline Testing in a Pediatric Cancer Predisposition Clinic

Lisa Schwartz, Ph.D. Children's Hospital of Philadelphia 2018 Grant

Surviving Cancer CAMPetently: Evidencebased Care Delivered at Family Camp

Melissa Alderfer, Ph.D. Nemours A.I. duPont Hospital for Children 2018 Grant

Reach Grants

\$250,000 over two years

This award is designed to move hypothesisdriven research toward the clinic. A successful application will identify an unmet clinical need relevant to the care of patients with pediatric cancer and describe how the work performed will allow for the translation of hypothesisdriven research to the clinic, keeping broader clinical testing and implementation in view.

Phase I study of lentivirus engineered autologous AML cells expressing IL-12 in children and young adults with relapsed

Michael Burke, M.D. Children's Hospital of Wisconsin 2017 Grant

Crazy 8

\$3M-5M over a four-year period

These large-scale collaborative grants are designed to bring together cross-disciplinary scientists to accelerate the pace of discovering new cures for currently incurable childhood cancers.

Barcoding Pediatric Leukemia for Therapeutic Purposes

Leonard Zon, M.D. Boston Children's Hospital 2020 Grant

Drugging MYCN

Yael Mossé, M.D. Children's Hospital of Philadelphia 2020 Grant

Small Molecule Degraders for Targeting Transcription Factor Drivers of Childhood Cancers

Charles Mullighan, MBBS (Hons), MSc, M.D. St. Jude Children's Research Hospital 2020 Grant

Tracking Ewing Sarcoma Origin by Developmental and Trans-species Genomics

Heinrich Kovar, Ph.D. St. Anna Children's Cancer Research Institute 2020 Grant

Young Investigator Grants

\$150,000 over three years

Young Investigator grants are designed to fill the critical need for startup funds for less experienced researchers to pursue promising research ideas. These grants encourage and cultivate the best and brightest researchers of the future and lead to long-term research projects. The Young Investigator selected by Northwestern Mutual also receive a \$10,000 equipment grant to supplement their research.

Improving Homing and Activity of CAR T Cells in Pediatric Sarcomas

Joselyn Cruz, Ph.D. University of Colorado Denver 2024 Grant

Investigating the Impact of Osteosarcoma Genetic Lesions on Bone Differentiation

James Morrow, M.D./Ph.D. Dana-Farber Cancer Institute 2024 Grant



Modifying CAR T Cell Epigenetic Programs to Improve Therapy Against Aggressive Pediatric Brain Tumors

Meghan Ward, Ph.D. St. Jude Children's Research Hospital 2024 Grant

Utilizing Chromatin Directed Inhibitors to Regulate Gene Expression in Ewing Sarcoma for Therapeutic Benefit

Justin Sperlazza, M.D./Ph.D. University of North Carolina 2024 Grant

A Novel Adjunctive LAT-Activating CART (ALA-CART) Cell Platform for the Treatment of Acute Leukemias

Catherine Danis, Ph.D. University of Colorado Denver 2023 Grant

Arginine Depletion with DFMO in High-Risk Neuroblastoma

Christina Turn, M.D. Children's Hospital of Philadelphia 2023 Grant

Synthetic Gene Expression Regulatory Switches (SynGERS) for Improved CAR T Cell Function in Pediatric Solid Tumors

Leidy Diana Caraballo Galva, Ph.D. Baylor College of Medicine 2023 Grant

Targeting the Checkpoint Receptor TIGIT via CRISPR/Cas9 Genome Editing to Enhance NK Cell Anti-Tumor Activity

Amanda Campbell, M.D./Ph.D. Research Institute at Nationwide Children's Hospital 2023 Grant

Activating Metabolic Pathways to Increase the Persistence of Leukemia Targeting T Cells

Erica Braverman, M.D. Children's Hospital of Pittsburgh 2021 Grant

Development of RNAi-based Therapeutics to Target Oncogenic IncRNAs in Rhabdomyosarcoma

Christian Tyler Stackhouse, Ph.D. Duke University 2021 Grant

Exploiting the Potential of Bromodomain Inhibitors in Ewing Sarcoma

Shireen Ganapathi, M.D. Seattle Children's Hospital 2021 Grant

Redefining Osteosarcoma Metastases as Chronic Non-healing Lung Wounds: Implications for Developing Novel Therapies

James Reinecke, M.D./Ph.D. Research Institute at Nationwide Children's Hospital 2021 Grant

Social Determinants of Health, Hospitallevel Resources, and Risk of Septic Shock in Pediatric Leukemia

Jenny Ruiz, M.D. Children's Hospital of Pittsburgh 2021 Grant

Dissecting the Role of FOXR2 in the Oncogenesis of Diffuse Intrinsic Pontine Glioma

Jessica Tsai, MD/PhD Dana-Farber Cancer Institute 2020 Grant

Using Neurofibromatosis-1 (NF1) to understand Pediatric Brain Tumor Initiation

Yuan Pan, PhD Stanford University School of Medicine 2020 Grant

High-throughput CAR NKT Library Screen for Improving Neuroblastoma Immunotherapy

Xavier Rios, MD/PhD Baylor College of Medicine 2020 Grant

Donor T-Cell DNA Methylation in GVHD and the Graft-vs-Tumor Effect after Allogeneic Hematopoietic Stem Cell Transplant

Yiouli Panayiota Ktena, MD The Johns Hopkins University School of Medicine 2020 Grant

Enhancing the Therapeutic Efficacy of Chimeric Antigen Receptor T cells for Acute Myeloid Leukemia

Miriam Kim, M.D. Washington University 2019 Grant

Improving CAR T-Cell Therapy for Pediatric Osteosarcoma by Manipulating Arginine Metabolism

Shannon Lange, Ph.D. St. Jude Children's Research Hospital 2019 Grant

Novel Genomic Drivers in Pediatric Polyposis Syndromes

Suzanne MacFarland, M.D. Children's Hospital of Philadelphia 2019 Grant

Targeting Valine-Specific Amino Acid Dependency in T-Cell Acute Lymphoblastic Leukemia

Palaniraja Thandapani, Ph.D. New York University Medical Center 2019 Grant

Interrogation of neuroblastoma dependencies and RNAs on the core-regulatory circuitry for therapeutic inhibition

Adam Durbin, M.D./Ph.D. Dana-Farber Cancer Institute 2018 Grant

Investigating the role of BAI1 in the metastasis of medulloblastoma

Satoru Osuka, M.D./Ph.D. Emory University 2018 Grant

Novel Antibodies to the C2-set Domain of CD33 for Acute Myeloid Leukemia Immunotherapy

Colin Godwin, M.D. Fred Hutchinson Cancer Research Center 2018 Grant

Therapeutic targeting of childhood leukemia by pharmacological inhibition of proteolytic cleavage of MLL1

Zibo Zhao, Ph.D. Northwestern University 2018 Grant

Development and Characterization of Novel Models of Human Osteosarcoma Development and Metastasis

Beau Webber, Ph.D. University of Minnesota 2017 Grant

High-Throughput Gene-Editing via Microfluidic Cell Deformability to Enable Off-the-Shelf Allogeneic Cellular Immunotherapies

Steven Jonas, M.D./Ph.D. University of California Los Angeles 2017 Grant

Identifying Disease Mechanisms and Therapeutic Opportunities in Pediatric Low-grade Gliomas Driven by MYB-QKI Fusions

Cecile Rouleau, Ph.D. Dana-Farber Cancer Institute 2017 Grant

The Impact of Hypoxia on Epigenetic Changes in Neuroblastoma

Sakshi Uppal, Ph.D. University of Chicago 2017 Grant

Bad Influence: EWS/FLI Alters LSD1 and NuRD Interactions to Enforce Oncogenic Function in Ewing Sarcoma

Emily Theisen, Ph.D. Research Institute at Nationwide Children's Hospital 2016 Grant

Young Investigator Summit Equipment Grants

To further support early career researchers in advancing the field of pediatric cancer research, Northwestern Mutual has generously provided equipment grants to attendees of Young Investigator Summits, as listed below.

Abhinav Dey, Ph.D. Emory University 2017 YI Summit Equipment Grant

Adam de Smith, Ph.D. University of California San Francisco 2017 YI Summit Equipment Grant

Alexandros Tzatsos, M.D./Ph.D. The George Washington University 2017 YI Summit Equipment Grant

Amanda DiNofia, M.D. The Children's Hospital of Philadelphia 2017 YI Summit Equipment Grant

Andrew Hong, M.D. Dana-Farber Cancer Institute 2017 YI Summit Equipment Grant

Asmin Tulpule, M.D./Ph.D. University of California San Francisco 2017 YI Summit Equipment Grant

Bradley Blaser, M.D./Ph.D. Boston Children's Hospital 2017 YI Summit Equipment Grant

Brenton Mar, M.D./Ph.D. Dana-Farber Cancer Institute 2017 YI Summit Equipment Grant

Carl Koschmann, M.D. University of Minnesota 2017 YI Summit Equipment Grant Conrad Russell Cruz, M.D./Ph.D. Children's Research Institute 2017 YI Summit Equipment Grant

Daniel Herranz, Ph.D. Institute for Cancer Genetics 2017 YI Summit Equipment Grant

David Debruyne, Ph.D.
Dana-Farber Cancer Institute
2017 YI Summit Equipment Grant

Elliot Stieglitz, M.D. University of California San Francisco 2017 YI Summit Equipment Grant

Emily Theisen, Ph.D. Research Institute at Nationwide Children's Hospital 2017 YI Summit Equipment Grant

Eric Hutton Raabe, M.D./Ph.D. The Johns Hopkins University School of Medicine 2017 YI Summit Equipment Grant

Genevieve Kendall, Ph.D. University of Texas Southwestern Medical Center 2017 YI Summit Equipment Grant

Glenson Samuel, M.D. University of Kansas Medical Center Research Institute 2017 YI Summit Equipment Grant

Ingo Koomoa-Lange, Ph.D. University of Hawaii 2017 YI Summit Equipment Grant

Jessica Linda Heath, M.D. University of Vermont 2017 YI Summit Equipment Grant

Kathleen Pishas, Ph.D. Research Institute at Nationwide Children's Hospital 2017 YI Summit Equipment Grant

Kevin Jones, M.D. University of Utah 2017 YI Summit Equipment Grant

Kristopher Sarosiek, Ph.D. Harvard T.H. Chan School of Public Health 2017 YI Summit Equipment Grant

Kyle Walsh, Ph.D. University of California San Francisco 2017 Yl Summit Equipment Grant

Lena Winestone, M.D. The Children's Hospital of Philadelphia 2017 YI Summit Equipment Grant

Madeline Hayes, Ph.D. Massachusetts General Hospital 2017 YI Summit Equipment Grant Mario Otto, M.D./Ph.D. University of Wisconsin - Madison 2017 YI Summit Equipment Grant

Nicole Anderson, Ph.D. University of Pennsylvania 2017 YI Summit Equipment Grant

Ranjini Sundaram, Yale University & School of Medicine 2017 YI Summit Equipment Grant

Robin Parihar, M.D./Ph.D. Baylor College of Medicine 2017 YI Summit Equipment Grant

Shuning He, Ph.D. Dana-Farber Cancer Institute 2017 YI Summit Equipment Grant

Stephen Mack, Ph.D. The Cleveland Clinic Foundation 2017 YI Summit Equipment Grant

Sunhye Lee, Ph.D. Children's Hospital Los Angeles 2017 YI Summit Equipment Grant

Yana Pikman, M.D. Dana-Farber Cancer Institute 2017 YI Summit Equipment Grant

Zhenyi An, Ph.D. University of California San Francisco 2017 YI Summit Equipment Grant

Crazy 8 Initiative Pilot Projects

\$200,000 over two years

To jump start the research ideas that came out of the Crazy 8 Initiative Meeting, ALSF supported 11 pilot projects in 2019, with at least one project for each Crazy 8 area of need.

Comprehensive Public Resource for Fusion-Negative Sarcoma Sequencing Data

Alejandro Sweet-Cordero, M.D. & Richard Gorlick, M.D. University of California San Francisco 2019 Grant

Live-Cell Surface Proteomic Characterization of Atypical Teratoid Rhabdoid Tumors Using High Throughout Multi-Color Flow

Alejandro Sweet-Cordero, M.D. & Siddhartha S. Mitra, Ph.D. University of Colorado Denver 2019 Grant



Supplemental Grants

Amount and timing may vary

While not specific to an official ALSF grant program, these Northwestern Mutual grants were uniquely positioned to meet areas of need within pediatric oncology.

ALSF Shark Tank: Hidden Drivers of Pediatric Low-Grade Glioma

Sean Misek, Ph.D. Broad Institute 2023 Grant

ALSF Shark Tank: Tracking Drug Resistance in FOXR2-expressing DMGs

Jessica Tsai, M.D./Ph.D. Children's Hospital Los Angeles 2023 Grant

ALSF Shark Tank: ARL2, the Villain We've been Looking for in Resistant Leukemias?

Sara Canovas Nunes, Ph.D. Boston Children's Hospital 2022 Grant

ALSF Shark Tank: Development of the Metastasis "Goo-Gone"

James Reinecke, M.D./Ph.D. Research Institute at Nationwide Children's Hospital 2022 Grant

ALSF Shark Tank: Dissecting Functional uORFs as a Source of Cancer Genes in High-Risk Medulloblastoma

John Prensner, M.D./Ph.D. University of Michigan 2022 Grant

YI Summit Resource Sharing Plan Award: Project in ZFTA-RELA Fusion Ependymoma

Austin Stuckert, M.D. Baylor College of Medicine 2022 Grant

ALSF Shark Tank: Bioinspired Nanotechnologies to Enable the Clinical Deployment of Next-Generation Cellular Immunotherapy

Steven Jonas, M.D./Ph.D. University of California Los Angeles 2017 Research Catalyst Grant

ALSF Shark Tank: The spliceosome as a synthetic lethal therapeutic target in pediatric solid tumors

Ronald Bernardi, M.D./Ph.D. Baylor College of Medicine 2017 Research Catalyst Grant

ALSF Shark Tank: Uncovering the Myc enhancer-ome in pediatric cancer

Daniel Herranz, Ph.D. Rutgers Cancer Institute of New Jersey 2017 Research Catalyst Grant

ALSF Shark Tank: Understanding the heterogeneity in neuroblastoma metastasis and response to targeted therapy

Shizhen Zhu, M.D./Ph.D. Mayo Clinic 2017 Research Catalyst Grant

ALSF Shark Tank: Unlocking DNA repair weaknesses with cancer organoids

Asmin Tulpule, M.D./Ph.D. University of California San Francisco 2017 Research Catalyst Grant





Your Special Event Support

For 12 years, Northwestern Mutual has never failed to show their devotion to childhood cancer families. Our special events are possible because of your outstanding support. As a Presenting Sponsor at L.A. Loves Alex's Lemonade to The Lemon Ball to The Great Chefs Event Philadelphia, it is your support that inspires so many to come together and raise money for critical childhood cancer research. For years, Northwestern Mutual has been a valued resource, a generous donor and an outstanding partner.

In 2023, your support helped L.A. Loves Alex's Lemonade make an extraordinary comeback. With your help, L.A. Loves Alex's Lemonade raised more than \$1.3 million for childhood cancer research. It was an afternoon of full stomachs and fuller hearts at UCLA as guests sampled delicious dishes and sweet treats from more than 50 superstar chefs while bidding on awesome auction items and making a difference.

To kick off 2024, your presence at The Lemon Ball will not soon be forgotten as John Schlifske, your Chairman, President and CEO, received the "Childhood Cancer Lifetime Achievement Award." Leading Northwestern Mutual with unwavering commitment to find a cure and fight to end childhood cancer is the kind of outstanding support that inspires a legacy – a legacy for John that includes more than \$50 million raised to fight childhood cancer (with over \$30 million contributed to ALSF). The generosity continued that night; as Northwestern Mutual surprised us with an incredible \$100,000 donation. Your support helped to raise more than \$900,000 that night as guests danced, dined, and dried their eyes after hearing the inspiring stories of the childhood cancer heroes we fight for every day.

By the time The Great Chefs Event Philadelphia came around in June, we knew it would be another satisfying day of food and fundraising. More than 800 guests came hungry to make a difference. Thanks to your sponsorship, 36 talented chefs were able to join forces with expert brewers, vintners, and mixologists to help raise more than \$550,000 for childhood cancer research.

Combined, these events raised more than \$2.5 million for kids with cancer. That's \$2.5 million that will go toward research that is finding safer, more effective treatments for kids everywhere. We are proud to partner with Northwestern Mutual on these special events this year, and for many more years to come!





#LemonTopChallenge




In 2023, Northwestern Mutual topped off all its stellar support with the #LemonTopChallenge, asking supporters to post their attempts at balancing a lemon atop their head. With every post, you donated \$10 to help kids with cancer. It all added up to more than \$100,000. That's a whole lot of research, and a whole lot of lemons on your heads!



You can't sit back and wait for a cure. You need to work to help other kids from having to go through the battle.

Doctors saved Jack because of meaningful research like what Alex's strives to provide."

Molly, childhood cancer hero Jack's mom





"If I didn't have that gas card, I don't know that I'd have gas money to get him to treatment. Every little penny counts."

— Jennifer, childhood cancer hero Elijah's mom

"I really appreciate the research ALSF helps fund. All ages are special and everyone should have an equal chance at life."

Shurice, childhood cancer hero Kingsley's mom



With your support, we have been able to improve the quality and length of life for children with cancer. This goes beyond research and treatments. Thanks to Northwestern Mutual programs like Pathfinder and the Holiday Hero gift exchange, you are helping us create an atmosphere of total care where families can receive emotional support in addition to financial services.

Paving the Path to Better Family Support

Stemming from Northwestern Mutual's Hack For Good Hack-a-Thon, Pathfinder is an app currently in development that will provide concise, accurate resources for childhood cancer families. It will give an individualized guide to assist parents, survivors, SuperSibs, those dealing with grief and more through their experience with childhood cancer journey. Its target launch date is currently late 2024 and Northwestern Mutual is continuing to work with us to develop it through funding and time dedicated from the team.

Pathfinder mission: "We want to help the mom sitting in a hospital room with her child at 3 am wondering where to start."

Helping Heroes for Holiday Season

This year, 21 Northwestern Mutual offices participated in the Holiday Hero gift exchange. This involved matching a childhood cancer hero family with a local office, which was then given the family's wish list. Employees were encouraged to interact with the families and get to know them before purchasing their dream holiday presents. Siblings, parents, and the heroes themselves were all included in the generous gift-giving.



"We are not alone thanks to foundations like yours."

 Bibiana, childhood cancer hero Francisco's mom





Fighting Childhood Cancer,

One Cup at a Time.

(866) 333-1213

AlexsLemonade.org

